CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.
Guérin
S
S
INSERM U292, Department of Epidemiology, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
Meyer
L
L
Theodorou
I
I
Boufassa
F
F
Magierowska
M
M
Goujard
C
C
Rouzioux
C
C
Debré
P
P
Delfraissy
J F
JF
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005500:Follow-Up Studies; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D016017:Odds Ratio; D019713:Receptors, CCR5 / Q000235:genetics* / Q000378:metabolism*; D017384:Sequence Deletion / Q000235:genetics*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D019713:Receptors, CCR5